Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control
Open accessAbstract
The COVID-19 pandemic's high mortality rate and severe socioeconomic impact serve as a reminder of the urgent need for effective countermeasures against viral pandemic threats. In particular, effective antiviral therapeutics capable of stopping infections in its tracks is critical to reducing infection fatality rate and healthcare burden. With the field of drug delivery witnessing tremendous advancement in the last two decades owing to a panoply of nanotechnology advances, the present review summarizes and expounds on the research and development of therapeutic nanoformulations against various infectious viral pathogens, including HIV, influenza, and coronaviruses. Specifically, nanotechnology advances towards improving pathogen- and host-targeted antiviral drug delivery are reviewed, and the prospect of achieving effective viral eradication, broad-spectrum antiviral effect, and resisting viral mutations are discussed. As several COVID-19 antiviral clinical trials are met with lackluster treatment efficacy, nanocarrier strategies aimed at improving drug pharmacokinetics, biodistributions, and synergism are expected to not only contribute to the current disease treatment efforts but also expand the antiviral arsenal against other emerging viral diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system or in a nanoparticle.
“Indeed, bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system204–206 or in a nanoparticle207–209.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [207]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 149 · Cited by 39
Research works printed but not linked: 1
- [48]das Neves J Michiels J Arien KK Vanham G Amiji M Bahia MF Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine Pharm Res. 2012 29 6 1468 1484 10.1007/s11095-011-0622-3 22072053 · DOI
- Authors
- Yang, K.-C., Lin, J.-C., Tsai, H.-H., Hsu, C.-Y., Shih, V., & Hu, C.-M. J.
- Affiliations
- National Yang Ming Chiao Tung University (TW)
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Corresponding author
- Hu, Che-Ming Jack
- Venue
- Drug Delivery and Translational Research
- Published
- 2021-03-21
- Volume
- 11
- Issue
- 4
- Pages
- 1420-1437
- ISSN
- 2190-393X (ISSN-L)
- 2190-3948
- PMC
- PMC7982277
- OpenAlex
- W3138198810
- Cited by
- 39
- References
- 149
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 5
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug Delivery and Translational Research (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (108-2119-M-001-016, 109-2321-B-002-033)
- Academia Sinica (AS-CDA-105-L06)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- antiviral drug delivery, nanocarriers, COVID-19 pandemic, SARS-CoV-2, HIV, influenza, coronavirus, broad-spectrum antivirals, virus resistance, pharmacokinetics, drug synergy, pandemic response
- MeSH terms
- COVID-19, Animals, Antiviral Agents, Humans, Virus Diseases, Virus Replication, Drug Delivery Systems, Nanotechnology, Nanoparticles, Host-Pathogen Interactions, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
